Guided by the spirit of the plenary session, now is the perfect time to sprint toward pharmaceutical safety.
Release time:
2025-12-12 14:21
Keywords:
Deployment,Productivity
As the year draws to a close and the final push intensifies, the sprint for December has already begun. This is the first time that Xixian New Area Guorui Yinuo Drug Safety Evaluation and Research Co., Ltd. (hereinafter referred to as “Guorui Yinuo”) has shared with everyone via its official WeChat account the practical integration of Party building and business operations. The company wishes to show you that the spirit of policies is never just a distant slogan—it is instead a down-to-earth guide deeply rooted in the laboratory, empowering every single piece of research. As a drug safety evaluation institution in Shaanxi Province that has obtained OECD GLP international accreditation, we are deeply committed to the field of non-clinical drug safety evaluation and one-stop R&D services for veterinary drugs (preclinical + clinical), taking on the responsibility of “safety gatekeeper” to safeguard innovation in the biopharmaceutical industry.
The “Suggestions of the CPC Central Committee on Formulating the 15th Five-Year Plan for National Economic and Social Development,” adopted at the Fourth Plenary Session of the 20th Party Congress, specifically lays out clear guidelines for “strengthening drug safety efforts and supporting the development of innovative drugs and medical devices.” Among these guidelines are requirements such as “enhancing core competitiveness,” “deepening reform and tackling tough challenges,” “developing new-quality productivity,” and “implementing full-lifecycle regulation”—all of which perfectly align with our key objectives as we enter the final stretch of this year. Today, rather than engaging in abstract theories, we’ll focus on one central question: How can we translate the spirit of the Plenary Session into precise data from GLP laboratories and professional non-clinical research services, using practical action to bring a successful conclusion to 2025?
01. Take the spirit of the plenary session as our guiding principle and pinpoint the right direction for our final sprint.
The Fourth Plenary Session of the 20th Central Committee of the Party’s strategic deployment for the biopharmaceutical industry is highly aligned with our sprint goals. The emphasis on “strengthening core competitiveness” clearly guides us to focus on our core business—non-clinical safety evaluation of drugs and one-stop R&D for veterinary medicines. We will prioritize tackling key challenges such as optimizing repeated-dose toxicity testing procedures, enhancing the precision of reproductive toxicity data, and perfecting the clinical validation system for veterinary medicines, thereby continuously reinforcing our professional strengths across the entire value chain. The call to “pool development efforts” requires us to break down departmental barriers, enabling close collaboration and efficient coordination among departments including experimentation, technology, quality control, and toxicology, particularly during the year-end period when projects are concentrated. The principle of “full-lifecycle regulation” reminds us to strictly adhere to GLP standards and the regulatory requirements for veterinary drug clinical trials, ensuring that our data are authentic, compliant, and capable of withstanding scrutiny by global regulatory agencies. Policy guidance serves as a precise navigational compass for our sprint toward success.
02. Put the spirit of practical action into practice and focus on accelerating our efforts.
Based on our company’s unique business characteristics, we’ve translated the spirit of the plenary session into concrete, targeted initiatives: We’ve identified gaps by comparing them against the annual project list; the experimental team has efficiently shortened the trial cycle; the business team has focused on expanding projects that meet the R&D needs for innovative drugs and pet medications; the technical team has been closely following cutting-edge evaluation technologies; and the administrative department has strengthened logistical support and process coordination. Party members have proactively taken on key and challenging tasks, stepping forward and shouldering heavy responsibilities in technological breakthroughs, compliance oversight, and project collaborations, thereby fostering an atmosphere of emulation, learning, and striving for excellence. All employees strictly adhere to regulatory requirements from multiple systems—including those set by the OECD and NMPA—meticulously scrutinizing every step from the ethics of laboratory animals to data recording and report review, and conducting year-end self-assessments for compliance. Through precise and pragmatic actions, we ensure both the quality and efficiency of our sprint efforts.
03. Sprint toward the future and pave the way for development.
The year-end sprint is not only aimed at achieving the 2025 targets but also represents a crucial practice for implementing the spirit of the plenary session and seamlessly connecting with the development of the biopharmaceutical industry during the 15th Five-Year Plan period. During this sprint, we are optimizing the entire “screening-evaluation-validation” process and overcoming technical challenges in automated experimental methods. These efforts will accumulate valuable experience for serving the northwest biopharmaceutical industry cluster in 2026 and expanding our multi-category business offerings, ensuring that the outcomes of our reform initiatives are effectively put into practice. Moreover, our steadfast commitment to aligning with the GLP system internationally is a concrete action to foster the core driving forces of “efficiency, precision, and compliance.” This not only enables us to better meet the safety evaluation needs across multiple product categories—including human pharmaceuticals, veterinary medicines, pet drugs, and pesticides—but also empowers the northwest biopharmaceutical industry to shift from following others to running alongside them. Through this sprint’s tangible results, we are putting into practice the plenary session’s strategic plan to “promote the building of a powerful pharmaceutical nation.”
For the first time together, we embark on a new journey through practical action.
For the first time, Guorui Yinuo is sharing its insights in the form of a Party-building article. Moving forward, the company will continue to integrate Party building into daily work in a down-to-earth and business-oriented manner. As we enter the final sprint phase, let us take the spirit of the Fourth Plenary Session as our guiding principle, unite our hearts and pool our efforts, overcome challenges through precise experimentation, enhance efficiency through collaborative teamwork, and ensure quality through compliant and pragmatic actions. Let us successfully achieve all our 2025 goals, kick off the new year of 2026 with practical achievements, and set a strong and promising foundation for the development of pharmaceutical safety during the 15th Five-Year Plan period.
Related News
Contact phone number
Ms. Li:+86 15760970681
Mr. Su:+86 19991001701
Landline:+86-29-33656828
Company Address
4th Floor, Unit C. Building 9. Small and Medium-sized
Enterprise Park, Airport Industrial Zone Airport New Ciy,Xixian New Area, Shaanxi Province
©2026 Xixian New Area Guorui Yinuo Drug Safety Evaluation and Research Co., Ltd.
WhatsApp：8613940397353
Email：hr-xian@grglp.com
Landline：862933656828
Mr. Su：8619991001701
Ms. Li：8615760970681